Other Publications
  • Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066˝73.
  • Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35(7):1245˝55.
  • Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195˝200.
  • Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjłgren's syndrome. Ann Rheum Dis. 2003;62(2):168˝71.
  • Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev. 2009 (in press).
  • Mackay F and Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465˝75.
  • Martin F and Chan AC. B cell immunology in disease: evolving concepts from the clinics. Annu Rev Immunol. 2006;24:467˝96.
  • Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600˝09.
  • Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev. 2005;204:43˝54.
  • Thaunat O, Natacha P, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean M, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85:1648-53.
  • Sarantopoulos S, Stevenson K, Kim H, Cutler C, Bhuiya N, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113:3865-74.
  • Levesque M. Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009;157:198-208.
  • Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008; 35:1256-64.
  • Eisenberg R and Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006; 2(1):20-27.
  • Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S, et al. Increase in B-cell-activation factor (BAFF) and IFN~? productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients IgA Nephropathy. J Clim. 2008; 126:260-69.
  • Xin G, Shi W, Xu L, Su Y, Yan L, Li K. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2012.
Back to Top